Cross-Disease Platform Approaches: How Shared Infrastructure and Collaborative Models Can De-Risk Next Gen Science for Patients

As scientific innovation accelerates, patient organizations face a growing challenge: how to invest upstream in ways that meaningfully de-risk and accelerate the therapeutic pipeline. Increasingly, cross‑disease platforms (i.e., shared research infrastructure, platform trial designs, and collaborative funding models) are emerging as some of the most powerful tools to speed progress not just for one condition but also across entire categories of disease. These approaches can offer solutions in areas where patient populations and resources may be limited. In this one‑hour TRAIN webinar, part of our Derisking Next‑Gen Science series, we explore how patient organizations can harness multi-disease strategies to maximize impact, reduce duplication, and drive faster translation to patients. 

Key Takeaways

• Platform approaches can improve efficiency across diseases and conditions. Grouping efforts by shared biology, delivery systems, or trial design can reduce duplication, manage risk, and enable progress for multiple patient populations simultaneously.
• Data quality and platform interoperability are essential for translation and scale. High-quality longitudinal data, standardized endpoints, and interoperable systems support stronger regulatory engagement and more sustainable progress—and once built, they don't stop being valuable.
• Patient organizations are critical enablers of innovation. By investing early in data stewardship, governance, and clinical networks, patient organizations lower barriers for researchers and industry while shaping development pathways that center patient needs.
• Regulatory systems can accommodate innovative and alternative development models. Master protocols, umbrella trials, and thoughtful use of real‑world data are increasingly viable within existing regulatory frameworks but require early regulatory engagement and coordination and shared standards to succeed.
• Reusable scientific components are redefining future therapies. Advances in gene and cell therapy delivery methods, data platforms, and analytic tools are shifting R&D toward adaptable models that can be applied across diseases rather than built from scratch each time.

Resources Mentioned

Webinar Slides

FA Global Clinical Consortium: FARA’s international clinical research network and natural history study infrastructure

Friedreich’s Ataxia Integrated Clinical Database: C-Path data-sharing platform hosting FARA natural history and trial data

Bespoke Gene Therapy Consortium (BGTC): NCATS-led public-private partnership developing AAV gene therapies across rare diseases

BGTC at the Foundation for the NIH: AMP program page with regulatory playbook and partner information

NIH Somatic Cell Genome Editing Program: NIH Common Fund program funding multi-disease genome editing clinical development, including the Baby KJ urea cycle disorder work

"How to Create Personalized Gene Editing Platforms" (AJHG, 2025): Ahrens-Nicklas and Musunuru's paper on the umbrella trial framework for urea cycle disorders

PedAL Master Clinical Trial: Blood Cancer United's first-of-its-kind global pediatric acute leukemia master trial

About TRAIN

This webinar was made available to patient organizations that participate in The Research Acceleration and Innovation Network (TRAIN), which comprises nearly 200 foundations interested in taking a strategic and entrepreneurial approach to funding medical research. TRAIN convenes forward-thinking groups to learn from each other and share their novel solutions with the rest of the medical research system. FasterCures accepts new organizations to TRAIN on an ongoing basis. There is no fee for the application or for membership. 

To learn more and apply, visit the TRAIN application. Please contact [email protected] for more information about TRAIN.